Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR-TKI plus bevacizumab vs EGFR-TKI in PD-L1 positive EGFR-mutant stage IIIB/IV NSCLC
ChiCTR2000039415Phase 4Recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Apr 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of erlotinib, gefitinib, icotinib, afatinib and bevacizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: 1-year progression-free survival rate. Started Apr 2020; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000039415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039415.